Find small signs of big risk—with hs-TnT testing

While troponin T (TnT) is recognized as a valuable biomarker for the diagnosis of myocardial infarction (MI) and prognosis in heart failure (HF), high-sensitivity troponin T (hs-TnT) has even greater capacity to aid in the prediction of adverse events and add powerful new insight to your cardiovascular risk assessments.

Part of the solution to identify previously undetected CVD risk

While standard lipid screening plays an important role in cardiovascular disease (CVD) risk assessment, it may not always be predictive of adverse events.

  • Traditional lipid panels may not provide a complete assessment of patient risk of CVD or associated events
  • Half of heart attacks and strokes occur in patients with “normal” LDL cholesterol levels1
  • Going beyond standard lipid panels to assess additional risk factors may provide deeper insights into the risk of your patients
Read more
Read less

A gateway to predicting risk of adverse events

The hs-TnT biomarker detects minor elevations in TnT concentration that may aid in the prediction of adverse cardiovascular events.

  • Clinical evidence shows that hs-TnT may help predict relative risk for coronary heart disease, stroke, and other adverse events2-7
  • Hs-TnT may detect previously undetectable levels of troponin T that demonstrate increased CVD risk in apparently healthy adults8
  • Including hs-TnT testing in your risk assessment protocol may provide valuable insight into your patient’s risk profile
Read more
Read less

Find the injury to intervene before it’s too late

TnT is associated with cardiac injury in a number of ways as listed below. Hs-TnT testing may help you identify injury so that you can intervene to help prevent adverse events.

  • Prolonged ischemia of the myocardium leads to death of cardiomyocytes and release of intracellular proteins, such as cardiac troponins, into circulation9
  • Minor increases of TnT may indicate ongoing, low-level cardiomyocyte injury that could be due to such mechanisms as overload, myocardial strain, or inflammation10
  • Troponin levels below the diagnostic cutoff of an MI but above the detectable limit using a high-sensitivity assay may help identify patients without any adverse cardiac history who are at risk of CVD and associated events2-4
Read more
Read less

Supported by clinical evidence: hs-TnT’s predictive utility

In a meta-analysis of general population studies, elevated hs-TnT is strongly associated with an increased risk of cardiovascular and all-cause mortality.11

  • In a review of more than 154,000 patients, detectable cardiac Tn concentrations below the diagnostic threshold for MI were associated with increased risk of CVD as well as death from coronary heart disease (CHD) and stroke5
  • A comparison of hs-TnT levels at first visit to a 6-year follow-up found that increases in hs-TnT were independently associated with incident CHD, death, and HF, while decreases were associated with reduced risk of the same outcomes12
  • In patients with chronic HF, hs-TnT is a strong and independent predictor of all-cause and cardiovascular mortality, and of hospitalization for cardiovascular causes13
Read more
Read less

Prevent the event

Adding the hs-TnT test to your cardiovascular risk assessment protocol may provide you with valuable patient insights.

Test Name

Test Code

CPT Codea

Troponin T, High Sensitivity (hs-TnT)



aThe CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Advancing care across the cardiometabolic continuum

The Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence is dedicated to helping prevent the costliest and most debilitating CV events—offering a comprehensive portfolio of advanced tests, access to emerging innovations and continuing medical education, enhanced reporting solutions, and focused patient counseling services.

You can also benefit from Quest’s solutions and services, including broad health plan coverage for improved patient access, Quanum Lab Services Manager for streamlined practice workflow, and the MyQuest patient portal and app for better patient engagement.

Identify injury early to intervene before it’s too late.

Learn more about our hs-TnT test.


Download the brochure


Review the clinical flyer


Learn about continuing medical education from Cleveland HeartLab


Connect with us today, and a Quest sales representative will be in touch


  1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
  2. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol. 2013;61:1753-1758.
  3. Oluleye OW, Folsom AR, Nambi V, et al. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013;23(2):66-73.
  4. Seliger SL, Hong SN, Christenson RH, et al. High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). Circulation. 2017;135(16):1494-1505.
  5. Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol. 2017;70(5):558-568.
  6. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503-2512.
  7. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494-2502.
  8. Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. Journal of the American Heart Association. 2014;3(1):e000403.
  9. Katrukha IA. Human cardiac troponin complex. Structure and functions. Biochemistry (Mosc). 2013;78(13):1447-1465.
  10. Jaffe AS, Wright RS. High-sensitivity cardiac troponin and primary prevention: an important new role. J Am Coll Cardiol. 2016;68(25):2729-2732.
  11. Van der linden N, Klinkenberg LJ, Bekers O, et al. Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine (Baltimore). 2016;95(52):e5703.
  12. McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol. 2016;1(5):519-528.
  13. Aimo A, Januzzi JL, Vergaro G, et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018;137(3):286-297.